{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:12:34Z","timestamp":1791353554039,"version":"4.3.1"},"reference-count":26,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1136\/bjophthalmol-2013-304072","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T03:15:11Z","timestamp":1387250111000},"page":"1016-1022","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease"],"prefix":"10.1136","volume":"98","author":[{"given":"Marta","family":"Sacchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Mantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mastropasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,12,16]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2013-304072-1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/09286580600801044","article-title":"The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists","volume":"13","author":"Clegg","year":"2006","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.1136\/bjophthalmol-2013-304072-2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"key-10.1136\/bjophthalmol-2013-304072-3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70085-X","article-title":"Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"key-10.1136\/bjophthalmol-2013-304072-4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"key-10.1136\/bjophthalmol-2013-304072-5","first-page":"S88","article-title":"Management of dry eye disease","volume":"14","author":"Lemp","year":"2008","journal-title":"Am J Manag Care"},{"key":"key-10.1136\/bjophthalmol-2013-304072-6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1398-9995.2010.02536.x","article-title":"Clinical trials in allergic conjunctivits: a systematic review","volume":"66","author":"Mantelli","year":"2011","journal-title":"Allergy"},{"key":"key-10.1136\/bjophthalmol-2013-304072-7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"key-10.1136\/bjophthalmol-2013-304072-8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00003226-199307000-00007","article-title":"Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2013-304072-9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sj\u00f6gren's syndrome","volume":"72","author":"Gunduz","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"key-10.1136\/bjophthalmol-2013-304072-10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2013-304072-11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2013-304072-12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jcrs.2005.10.034","article-title":"Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis","volume":"32","author":"Salib","year":"2006","journal-title":"J Cataract Refract Surg"},{"key":"key-10.1136\/bjophthalmol-2013-304072-13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.icl.0000170599.57728.29","article-title":"An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye","volume":"32","author":"Sall","year":"2006","journal-title":"Eye Cont Lens"},{"key":"key-10.1136\/bjophthalmol-2013-304072-14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/ICL.0b013e3180676d44","article-title":"Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes","volume":"34","author":"Willen","year":"2008","journal-title":"Eye Cont Lens"},{"key":"key-10.1136\/bjophthalmol-2013-304072-15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1442-9071.2009.02090.x","article-title":"Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye","volume":"37","author":"Guzey","year":"2009","journal-title":"Clin Experiment Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2013-304072-16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","article-title":"A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome","volume":"147","author":"Kim","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2013-304072-17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/eye.2009.246","article-title":"Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients","volume":"24","author":"Altiparmak","year":"2010","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2013-304072-18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.2008.150011","article-title":"A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome","volume":"94","author":"Baiza-Duran","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2013-304072-19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2013-304072-20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.2009.0091","article-title":"Topical cyclosporine 0.05% for the prevention of dry eye disease progression","volume":"26","author":"Rao","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2013-304072-21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/ICL.0b013e31822563be","article-title":"Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome","volume":"37","author":"Demiryay","year":"2011","journal-title":"Eye Cont Lens"},{"key":"key-10.1136\/bjophthalmol-2013-304072-22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/jop.2011.0073","article-title":"Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal","volume":"27","author":"Rao","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2013-304072-23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/ICO.0b013e318206caee","article-title":"The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1\u2005year of twice-daily therapy","volume":"30","author":"Su","year":"2011","journal-title":"Cornea"},{"key":"key-10.1136\/bjophthalmol-2013-304072-24","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2013-304072-25","first-page":"548","article-title":"Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca","volume":"229","author":"Schrell","year":"2012","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.1136\/bjophthalmol-2013-304072-26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtos.2013.02.002","article-title":"Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies","volume":"11","author":"Alves","year":"2013","journal-title":"Ocul Surf"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2013-304072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:45:54Z","timestamp":1601109954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2013-304072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,16]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,7,18]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1136\/bjophthalmol-2013-304072"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304072","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,16]]}}}